CAPR•benzinga•
Oppenheimer Initiates Coverage On Capricor Therapeutics with Outperform Rating, Announces Price Target of $14
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 17, 2024 by benzinga